U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

(MARK ONE)

     [ X ]     QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
               EXCHANGE ACT OF 1934

                       For the quarter ended June 30, 1999

     [   ]     TRANSITION REPORT UNDER SECTION 13 OR A5(d) OF THE SECURITIES
               EXCHANGE ACT OF 1934  (no fee required)



                         Commission file number 0-23544

                         HUMAN PHERONONE SCIENCES, INC.
                  ---------------------------------------------
                 (Name of small business issuer in its charter)

              California                                 94-3107202
---------------------------------------      -----------------------------------
    (State or other jurisdiction of          (I.R.S.employee Identification No.)
     incorporation or organization)

4034 Clipper Court, Fremont, California                   94538
---------------------------------------      -----------------------------------
(Address of principal executive offices)                (Zip code)


                    Issuer's telephone number: (510) 226-6874
                                               --------------





           Check  whether the Issuer (1) filed all reports  required to be filed
by  Section  13 or 15(d) of the  Exchange  Act during the past 12 months (or for
such shorter period that the registrant was required to file such reports),  and
(2) has been subject to such filing  requirements  for the past 90 days. Yes [X]
No [ ]


                   (APPLICABLE ONLY TO CORPORATE REGISTRANTS)

           State  the  number  of  shares  outstanding  of each of the  issuer's
classes of common equity, as of the latest practicable date. 3,429,839 shares of
Common Stock as of August 6, 1999


                                                                 Total Pages: 13


                                       1

<PAGE>

<TABLE>

                                           HUMAN PHEROMONE SCIENCES, INC.

                                                       INDEX
                                                                                                               Page
                                                                                                               ----
<CAPTION>
<S>      <C>                                                                    <C>                               <C>
PART I
FINANCIAL INFORMATION

         Item 1. Financial Statements

                  Condensed Balance Sheets (Unaudited) as of June 30, 1999
                  and December 31, 1998...........................................................................4

                  Statements of Operations (Unaudited) for the Three Months and Six Months Ended
                  June 30, 1999 and 1998..........................................................................5

                  Condensed Statements of Cash Flows (Unaudited) for the Six Months
                  Ended June 30, 1999 and 1998....................................................................6

                  Notes to Condensed Financial Statements (Unaudited).............................................7

         Item 2. Management's Discussion and Analysis

                  Management's Discussion and Analysis of Financial Condition and Results of Operations...........8

PART II
OTHER INFORMATION


         Item 4. Submission of Matter to Vote of Security Holders................................................12


         Item 6. Exhibits and Reports on Form 8-K................................................................12

SIGNATURES.......................................................................................................13

</TABLE>

                                                         2

<PAGE>

                                     PART I
                              FINANCIAL INFORMATION


Item 1.  Financial Statements


                                       3

<PAGE>

<TABLE>
                                      Human Pheromone Sciences, Inc.

                                              Balance Sheets
<CAPTION>
                                                                             June 30,
                                                                               1999                    December 31,
                                                                           (unaudited)                    1998
                                                                         ----------------          -----------------
<S>                                                                     <C>                       <C>
Assets

Current assets:
  Cash and cash equivalents                                             $          80,832         $           76,696
  Accounts receivable, net of allowances of $67,526                             1,700,117                  2,051,574
   and $677,735 in 1999 and 1998, respectively
  Inventory                                                                     2,660,609                  2,894,541
  Other current assets                                                            123,468                    113,635
                                                                         ----------------          -----------------
Total current assets                                                            4,565,026                  5,136,446

Property and equipment, net                                                        34,555                     58,596
                                                                         ----------------          -----------------

                                                                        $       4,599,581         $        5,195,042
                                                                         ================          =================


Liabilities and shareholders' equity



  Loan payable, bank                                                    $         900,000         $          773,534
  Accounts payable                                                                625,720                    691,674
  Accrued advertising                                                             346,200                    553,926
  Accrued commissions                                                             334,681                    448,051
  Other accrued expenses                                                          337,756                    318,228
                                                                         ----------------          -----------------
Total current liabilities                                                       2,544,357                  2,785,413


Shareholders' equity:
  Convertible  preferred  stock,  issuable in series,  no par value,
    10,000,000 shares authorized,  1,445,716 and 1,439,333 shares
    issued and outstanding at June 30, 1999 and
    December 31, 1998, respectively                                             3,045,535                  2,745,535
  Common stock, no par value,  40,000,000  shares  authorized,
    3,429,839 shares issued and outstanding at June 30, 1999
    and December 31, 1998, respectively
                                                                               17,667,024                 17,667,024
  Accumulated deficit                                                         (18,609,722)               (18,002,930)
  Accumulated other comprehensive income:
      Foreign currency translation                                                (47,613)                         -
                                                                         ----------------          -----------------
Total shareholders' equity                                                      2,055,224                  2,409,629
                                                                         ----------------          -----------------

                                                                        $       4,599,581         $        5,195,042
                                                                         ================          =================

<FN>
See accompanying notes.
</FN>
</TABLE>

                                                          4

<PAGE>

<TABLE>
                                                 Human Pheromone Sciences, Inc.

                                                    Statements of Operations
                                                           (unaudited)
<CAPTION>

                                                          Three months ended June 30,            Six months ended June 30,
                                                          ---------------------------            -------------------------


                                                       --------------     ---------------     --------------     --------------
                                                           1999                1998               1999               1998
                                                       --------------     ---------------     --------------     --------------
<S>                                                    <C>                <C>                 <C>                <C>
Net sales                                              $   2,110,782      $    1,905,257      $   4,349,875      $   5,268,418
Cost of goods sold                                           757,205             627,074          1,536,026          1,671,273
                                                       --------------     ---------------     --------------     --------------

Gross profit                                               1,353,577           1,278,183          2,813,849          3,597,145

Expenses:
   Research and development                                   82,674             100,316            166,706            182,448
   Selling, general and administrative                     1,538,278           2,560,547          3,201,394          5,560,142
                                                       --------------     ---------------     --------------     --------------

Total expenses                                             1,620,952           2,660,863          3,368,100          5,742,590
                                                       --------------     ---------------     --------------     --------------

Loss from operations                                        (267,375)         (1,382,680)          (554,251)        (2,145,445)

Interest income                                                   90                 106                154                162
Interest (expense)                                           (23,651)            (10,514)           (46,172)           (21,469)
Other (expense)                                               (8,726)             (2,783)            (6,523)            (2,189)
                                                       --------------     ---------------     --------------     --------------

Loss before income taxes                                    (299,662)         (1,395,871)          (606,792)        (2,168,941)

Income taxes                                                  -                  -                   -                  -
                                                       --------------     ---------------     --------------     --------------

Net loss                                               $    (299,662)     $   (1,395,871)     $    (606,792)        (2,168,941)
                                                       ==============     ===============     ==============     ==============

Net loss per common share-basic                        $        (.09)     $         (.41)     $        (.18)     $        (.63)
                                                       ==============     ===============     ==============     ==============

Net loss per common share-
  assuming dilution                                    $        (.09)     $         (.41)     $        (.18)     $        (.63)
                                                       ==============     ===============     ==============     ==============

Weighted average shares used in calculation
  of net loss per share                                    3,429,839           3,429,839          3,429,839          3,429,839
                                                       ==============     ===============     ==============     ==============

Weighted average shares and equivalents,
  if dilutive, used in calculation of net loss
  per common share                                         3,429,839           3,429,839          3,429,839          3,429,839
                                                       ==============     ===============     ==============     ==============

<FN>
See accompanying notes.
</FN>
</TABLE>

                                                               5

<PAGE>

<TABLE>
                                     Human Pheromone Sciences, Inc.

                                        Statements of Cash Flows
                                              (unaudited)
<CAPTION>

                                                                     Six months ended June 30,
                                                                     -------------------------

                                                                     1999                   1998
                                                               -----------------      -----------------
<S>                                                            <C>                    <C>
Cash flows from operating activities
Net loss                                                       $       (606,792)     $      (2,168,941)
Adjustments to reconcile net loss
  to net cash used in operating activities:
  Depreciation and amortization                                          24,041                 29,612

  Changes in operating assets and liabilities:
    Accounts receivable                                                 351,457              2,230,348
    Inventory                                                           233,932                190,978
    Other current assets                                                 (9,833)                21,833
 Accounts payable and accrued liabilities                              (367,522)              (130,834)
                                                               -----------------      -----------------
Net cash provided by (used in) operating activities                    (374,717)               172,996

Cash flows from investing activities
Purchase of property and equipment                                    -                        (12,457)
                                                               -----------------      -----------------
Net cash used in investing activities                                 -                        (12,457)


Cash flows from financing activities
Proceeds from bank borrowings                                           900,000              2,495,296
Repayment of bank borrowings                                           (773,534)            (2,834,000)
Proceeds from issuance of convertible preferred stock                   300,000               -
                                                               -----------------      -----------------
Net cash provided by (used for) financing activities                    426,466               (338,704)

Effect of exchange rate changes on cash                                 (47,613)              -
                                                               -----------------      -----------------

Net increase/(decrease) in cash and cash equivalents                      4,136               (178,165)
Cash and cash equivalents at beginning of the year                       76,696                248,617
                                                               -----------------      -----------------
Cash and cash equivalents at end of the period                 $         80,832       $         70,452
                                                               =================      =================


<FN>
See accompanying notes.
</FN>
</TABLE>

                                                   6

<PAGE>

                         Human Pheromone Sciences, Inc.

                     Notes to Condensed Financial Statements
                                   (unaudited)

                                  June 30, 1999

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

         The accompanying  unaudited  condensed  financial  statements have been
prepared in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-QSB and Rule 10-01 of
Regulation  S-X.  Accordingly,  they do not include all of the  information  and
footnotes  required by generally  accepted  accounting  principles  for complete
financial statements. In the opinion of management,  all adjustments (consisting
of normal recurring accruals)  considered necessary for a fair presentation have
been included.  Operating results for the three months and six months ended June
30, 1999 are not necessarily  indicative of the results that may be expected for
the calendar year ending December 31, 1999. These condensed financial statements
should be read in conjunction with the Company's  audited  financial  statements
and footnotes thereto included in the Company's annual report on Form 10-KSB for
the year ended December 31, 1998.

Reverse Stock Split

         The  Company's  shareholders  approved  a 1 for 3 reverse  stock  split
effective April 13, 1999. All share and per share amounts have been adjusted for
the effects of the reverse split for all periods presented.

Inventory

         Inventories  are  stated  at the  lower of cost  (first  in - first out
method) or market.  The  inventory at June 30, 1999  consists of finished  goods
inventory  valued at $886,834  work in process of $238,388 and raw  materials of
$1,535,387.  At December 31, 1998, these balances were $1,114,443,  $264,599 and
$1,515,499, respectively.

Comprehensive Loss

         Comprehensive  loss for the quarter  ended June 30,  1999 was  $310,228
compared to $1,395,871 for the quarter ended June 30, 1998.  Comprehensive  loss
for the six months ended June 30, 1999 was $654,405  compared to $2,168,941  for
the six months ended June 30, 1998.


                                       7

<PAGE>

Item 2. Management's Discussion and Analysis

         This report contains  forward-looking  statements within the meaning of
Section 27A of the  Securities  Act of 1933, as amended,  and Section 21E of the
Securities  Exchange  Act  of  1934,  as  amended.  Except  for  the  historical
information contained in this discussion and analysis of financial condition and
results  of  operations,  the  matters  discussed  herein  are  forward  looking
statements.  These forward looking statements include but are not limited to the
Company's  plans for sales  growth and  expansion  into new  channels  of trade,
expectations  of gross  margin,  expenses,  new  product  introduction,  and the
Company's   liquidity  and  capital  needs.  These  matters  involve  risks  and
uncertainties  that could cause  actual  results to differ  materially  from the
statements made. In addition to the risks and  uncertainties  described in "Risk
Factors",  below,  these risks and  uncertainties  may include  consumer trends,
business cycles,  scientific  developments,  changes in governmental  policy and
regulation,  currency  fluctuations,  economic  trends in the United  States and
inflation. These and other factors may cause actual results to differ materially
from those anticipated in forward-looking statements.  Readers are cautioned not
to place undue reliance on these forward-looking statements, which speak only as
of the date hereof.

Risk Factors

         The  Company's  future  results  may be affected to a greater or lesser
degree by the following factors among others:

         The  Company  may  not be  able  to  effectively  compete  with  larger
companies  or with new  products.  The  prestige  fragrance  market is extremely
competitive.  Many  fragrance  products  are  better  known  than the  Company's
products and compete for  advertising and retail shelf space.  Many  competitors
have  significantly  greater  resources  that will  allow  them to  develop  and
introduce new competing  products or increase the promotion of current  products
more easily and effectively than the Company.

         The  product  life cycle of a  fragrance  can be very  short.  Changing
fashions  and fads can  dramatically  shift  consumer  preferences  and demands.
Traditional  fragrance  companies  introduce a new  fragrance  every year or so.
Changing  fashions and new products may reduce the chance of creating  long term
brand loyalty to the Company's products.

         The Company's marketing strategy may not be successful. The Company may
not be able to  establish  and  maintain the  necessary  sales and  distribution
channels.  Retail  outlets and  catalogs  may choose not to carry the  Company's
products.  The Company may not have sufficient funds to successfully  market its
products if the current marketing strategy is not successful.

         The  current  retail  environment  may cause  pricing  and  promotional
pressures. Four companies,  Federated Department Stores, The May Company, Dayton
Hudson/Marshall  Fields and Dillard Department Stores, own the majority of upper
end  department  stores.  Because  of  their  market  share,  each  company  has
significant  power to determine the price and promotional terms that the Company
must meet in order to sell its products in the company's department stores.

         Upper end  department  stores face  increasing  competition by discount
perfumeries,  drug  chains  and  lower  priced  department  stores  for sales of
fragrances  and  cosmetics.  To compete,  upper end  department  stores have cut
inventories,  reduced co-op advertising, and increased promotions. These tactics
may  force  the  Company  to  reduce  its  prices  or  increase  the cost of its
promotions.

         Seasonality  in sales  may cause  significant  variation  in  quarterly
results.  Sales in the  fragrance  industry are  generally  seasonal  with sales
higher in the second half of the year  because of  Christmas.  This  seasonality
could  cause  a  significant  variation  in the  Company's  quarterly  operating
results.

         The Company not be able to protect its technology or trade secrets. The
Company's  patents  and  patent  applications  may  not  protect  the  Company's
technology or ensure that the Company's  technology does not infringe  another's
valid  patent.  Others  may  independently   develop  substantially   equivalent
proprietary information.  The Company may not be able to protect its technology,
proprietary information or trade secrets.


                                       8

<PAGE>

         The Company may not be able to recruit  and retain key  personnel.  The
Company's  success  substantially  depends upon  recruiting  and  retaining  key
employees and  consultants  with  research,  product  development  and marketing
experience.  The Company may not be successful in recruiting and retaining these
key people.


         The Company relies upon other  companies to  manufacture  its products.
The  Company  relies  upon  Pherin  and  other   companies  to  manufacture  its
pheromones,  supply  components,  and to blend,  fill and package its  fragrance
products.   The  Company  may  not  be  able  to  obtain  or  retain   pheromone
manufacturers,  fragrance  suppliers,  or component  manufacturers on acceptable
terms.  If not, the Company may not be able to obtain  commercial  quantities of
its products. This would adversely affect operating results.

Results of Operations

Three  Months ended June 30, 1999 as compared to the Three Months ended June 30,
1998

         Net sales for the second quarter of 1999 were  $2,110,782  representing
an increase of 11% from sales of $1,905,257 for the prior year's quarter.  Sales
to secondary markets increased by 79% compared to the same quarter last year due
to increased demand from this segment of the business.  Revenue from the sale of
its human  pheromone  products  under its  initial  supply  agreement  with Avon
Products, Inc. contributed 18% of the current quarter's net sales. A 39% decline
of department  store sales is consistent with the Company's stated goal for 1999
to more  directly  focus selling and  marketing  efforts in a reduced  number of
department  stores  which have the  potential to be  profitable  partners in the
Realm(R) fragrance business.

         In 1999 a U.S. distributor,  which is considered a domestic customer of
the Company began selling to  international  markets  previously  being serviced
directly  by the  Company,  thereby  causing a  decrease  in  reported  sales to
international markets. International shipments have also declined since pipeline
sales were made into new markets in 1998;  there were no such pipeline  sales in
1999. Net sales for the quarters ended June 30, 1999 and 1998 were as follows:

================================================================================
Markets                                          1999                  1998
--------------------------------------------------------------------------------

  U.S. Markets                             $     1,984,659       $     1,580,844
  International Markets                            126,123               324,413
                                           ---------------       ---------------

  Net Sales                                $     2,110,782       $     1,905,257


         Gross  profit for the  quarter  ended  June 30,  1999  increased  6% to
$1,353,577  from $1,278,183 in the prior year due to higher sales resulting from
the supply agreement with Avon which began in 1999.  Slight  improvements in the
secondary  and  international  margins were offset by  decreased  margins in the
department store business.

         Research and  Development  expenses for the second quarters of 1999 and
1998 were $82,674 and $100,316,  respectively.  These costs principally  reflect
payments  and  costs  under  the   Company's   research   contract  with  Pherin
Pharmaceuticals.

         Operating  expenses  decreased  $1,022,269  to $1,538,278 in the second
quarter of 1999 from $2,560,547 in the second quarter of 1998. While $819,317 of
this  decrease was  attributable  to lower  advertising,  selling and  marketing
costs,  all operational  areas  decreased.  The 40% reduction in spending is the
result of the  Company's  plan to  execute a more  focused  sales and  marketing
strategy and a more  focused  expense  budget.  The second  quarter  results are
consistent with the Company's 1999 sales and marketing plan that anticipated the
decrease in sales and gross margin, with offsetting savings in spending.

         The Company  incurred  $23,561 in net interest expense during the first
quarter of 1999  compared to $10,408 net interest  expense in 1998 due to higher
average borrowings.


                                       9

<PAGE>

Six Months ended June 30, 1999 as compared to the Six Months ended June 30, 1998

         Net sales for the six months ended June 30, 1999 were $4,349,875.  This
was a 17%  decrease  from net sales of  $5,268,418  for the first  half of 1998.
Revenue from the sale of the Company's human pheromones under a supply agreement
with Avon Products,  Inc.  which  commenced in 1999, and a 29% increase in sales
for the secondary  markets,  catalog  companies and direct  marketing,  offset a
significant  portion of the 44%  decline in U.S.  department  store  sales.  The
decline in the department store sales is attributable to the late 1998 reduction
in the number of stores with whom the Company does  business,  and to the stated
Company  goal to focus on  accounts  that have the  potential  to be  profitable
partners.

In 1999 a U.S.  distributor,  that is  considered  a  domestic  customer  of the
Company  began  selling  to  international  markets  previously  being  serviced
directly by the  Company,  thereby  causing a decrease in reported  sales to the
international markets. International shipments have also declined since pipeline
sales were made into new markets in 1998;  there were no such sales in 1999. Net
sales for the six months ended June 30, 1999 and 1998 are as follows:

================================================================================
Class of Trade                                   1999                  1998
--------------------------------------------------------------------------------

  U.S. Markets                             $     4,098,448       $     4,533,071
  International Markets                            251,427               735,347
                                           ---------------       ---------------

  Net Sales                                $     4,349,875       $     5,268,418


         Gross profit for the first half of 1999 declined 22% to $2,813,849 from
$3,597,145  in 1998.  The  decrease  is  primarily  the result of reduced  sales
volume,  in addition to the increased sales to the lower gross margin  secondary
sales channel.

         Research and  Development  expenses for the first half of 1999 and 1998
were  $166,706  and  $182,448,  respectively  and are  principally  comprised of
payments under the Company's contract with Pherin Corporation.

         Operating expenses decreased to $3,201,394 in the six months ended June
30, 1999 from  $5,560,142 in the period ended June 30, 1998.  Selling  marketing
and  advertising  accounted for $2,111,372 of the decrease with all  operational
areas  also  spending  less in 1999  than  in  1998.  The  reduced  spending  is
consistent with the Company's 1999 sales and marketing plan that anticipated the
decrease in sales and gross profit, with offsetting savings in spending.

         The Company  incurred  $46,018 in net interest expense during the first
half of 1999  compared  to $21,307  net  interest  expense in 1998 due to higher
average borrowings during the period.

LIQUIDITY

         At June 30, 1999, the Company had a $3,000,000 line of credit,  against
which it had borrowed $900,000; its working capital was $2,020,670.  At June 30,
1998  the  Company  had net  borrowings  of  $209,296  and  working  capital  of
$2,178,013.  For the  first  six  months  of 1999,  net cash  used in  operating
activities was $374,717  compared to net cash provided of $172,996 for the prior
year's six-month period. Assuming the Company's activities proceed substantially
as  planned,  the  Company's  line of credit,  additional  equity  capital  from
preferred  stock  issuance,  and  anticipated  revenues  from product  sales and
technology  licensing  is expected  to be  adequate to meet its working  capital
needs over the next twelve months.  Working capital  requirements will primarily
be for the supply of inventory and accounts receivable financing.

         Additional  working  capital may be required should the Company fail to
generate  consumer  response  levels  as  planned  for  in  1999.   Furthermore,
additional  working  capital may be required  should the  Company  experience


                                       10

<PAGE>

a greater  than  planned  success  with its  products,  potential  product  line
extensions,  and department store marketing  efforts.  Funds would be needed for
inventory build-up,  accounts receivable financing and staffing purposes. If the
Company  fails  to  achieve  revenues  from its 1999  marketing  efforts,  or if
expansion  proves to be more capital  intensive  than  planned,  the Company may
require additional funding.


Impact of Year 2000

         The  Company  has  completed  a  comprehensive  review of its  internal
computer systems to identify the issues expected to arise in connection with the
Year  2000.  The  Company  is in the  process  of  reviewing  the  status of its
customers  and  suppliers  with regard to this issue and assessing the potential
impact of non-compliance by such parties on the Company's operations.

         The Company utilizes a server-based system for its material management,
manufacturing,  EDI  interface,  and  financial  systems.  Year  2000  compliant
software  upgrades  from the  vendors  have  been  installed,  and  tested  with
satisfactory  results.  The total cost to upgrade  and test the systems was less
than $20,000.

         The Company has also  completed its review of non-server  based systems
and equipment (telephone system, fax machines, and off-the-shelf software). This
review found that hardware was Year 2000 compliant, and that only a few software
titles contained non-compliant Year 2000 date calculation errors. These software
titles will be upgraded to more recent Year 2000 compliant versions later in the
year if it is determined  that the software is still needed by the Company.  The
financial impact is expected to be minimal.

         The Company is in the process of determining the extent to which it may
be impacted by third party systems,  which may not be Year 2000  compliant.  The
Year 2000  computer  issue  creates risk for the Company from third parties with
whom the  Company  deals on  financial  transactions.  To date the  Company  has
received assurances from its key customers, and suppliers that they will be Year
2000 compliant.  While the Company is receiving  reassurance from it's customers
and  suppliers,  there can be no assurance  that the systems of other  companies
that the Company  deals with or on which the  Company's  systems rely on will be
timely  converted,  or that any such failure to convert by another company could
not have an adverse effect on the Company.

         Contingency plans for suppliers, or customers that may not be compliant
are part of the Company's  material  planning process and sales planning for the
second half of 1999.  Failure to complete any necessary  remediation by the Year
2000 may have a material adverse impact on the operations of the Company.


                                       11

<PAGE>

                                     PART II
                                OTHER INFORMATION

Item 4.  Submission of Matters to Vote of Security Holders

         Registrant held a Special Meeting of shareholders on April 12, 1999. At
the Special Meeting, the shareholders voted on, and approved an amendment to the
Company's  Articles of  Incorporation  to effect a  one-for-three  reverse stock
split of the Company's Common Stock.
<TABLE>
         The number of votes cast for, against or withheld as well as the number
of abstention and broker non-votes as to the  one-for-three  reverse stock split
proposal are set forth below:
<CAPTION>
Proposal:                                For                 Against            Abstained          Broker
---------                                ---                 -------            ---------          ------
                                                                                                       Non-Votes
                                                                                                       ---------
<S>                                      <C>                  <C>                 <C>                       <C>
Amend the Company's Articles of
Incorporation to effect a
one-for-three reverse stock of the       6,406,337            76,319              2,200                     0
Company's Common Stock.
</TABLE>


Item 6.  Exhibits and Reports on Form 8-K

         None


<PAGE>

                                   SIGNATURES


         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  had duly  caused  this  Report  to be  signed  on behalf by the
undersigned thereunto duly authorized.


                                          HUMAN PHEROMONE SCIENCES, INC.
                                          Registrant




Date:  August 10, 1999                    /s/ William P. Horgan
                                          ------------------------------
                                              William P. Horgan
                                          Chairman and Chief Executive Officer




Date:  August 10, 1999                    /s/ Gregory S. Fredrick
                                          ------------------------------
                                              Gregory S. Fredrick
                                          Vice President, Controller